You are here

P&T September 2013

Features

Tighter Federal Steps Aim to Deflate Crisis
Hospitals and their pharmacy departments are now at the epicenter of the prescription drug-abuse tsunami. The Obama administration is using regulatory agencies in an to attempt to crack down on physician-run “pill mills” and the pharmacies that support them.
The authors found that two-thirds of drugs approved by the FDA in recent years lacked adequate efficacy and safety information for use in older patients. With an expected doubling of the elderly population by 2040, it is time for pharmaceutical manufacturers to incorporate more robust prescribing information into their product labels of drugs used in this patient population.
Part 1: The Clinical Significance of Pharmacogenetic Variants

As genotyping and genetic testing become more sophisticated, accessible, and costeffective, these tools hold great promise for predicting and improving responses to medications.

Controversies in Practice
A Closer Look at Media Messages Versus Research Findings
Although fish and fish oil supplements have been touted for their many benefits, especially in the treatment of cardiovascular disease, recent headlines have suggested that they might be linked to an increased risk of prostate cancer. P&T takes a closer look behind the mixed messages.

Departments

Medication Errors
Mixups with local and topical epinephrine have led to fatalities.
Prescription: Washington
Drug companies push to rein in 340B discount drugs.

FDA approvals, drug indications, and updates

Afatinib (Gilotrif) for non–small-cell lung cancer; golimumab (Simponi Aria) for moderate-to-severe active rheumatoid arthritis; and levomilnacipran (Fetzima) extended release for major depressive disorder

Drug Forecast